Transparency notification – Gilead holds 22% of Galapagos shares
August 28 2019 - 4:01PM
Mechelen, Belgium; 28
August 2019; 22.01 CEST; regulated information – Galapagos
NV (Euronext & NASDAQ: GLPG) received a transparency
notification from Gilead Sciences, Inc.
Pursuant to Belgian transparency legislation1,
Galapagos received a transparency notification on 28 August 2019
from Gilead Sciences, Inc. (acting as a parent undertaking or a
controlling person), who notified that Gilead Therapeutics A1
Unlimited Company, an indirect subsidiary of Gilead Sciences, holds
13,589,686 of Galapagos' voting rights, consisting of 13,589,686
ordinary shares, as a result of subscribing to a capital increase
and thus receiving 6,828,985 new Galapagos shares on 23 August
2019. This represents 22.04% of Galapagos' currently outstanding
61,652,086 shares. Gilead Therapeutics A1 Unlimited Company thus
crossed above the 20% threshold of Galapagos' voting rights by
acquisition of voting securities on 23 August 2019.
The notification specifies furthermore that (i)
Gilead Therapeutics A1 Unlimited Company is a direct subsidiary of
Gilead Biopharmaceutics Ireland UC, (ii) Gilead Biopharmaceutics
Ireland UC is a direct subsidiary of Gilead Sciences, Inc., and
(iii) Gilead Sciences, Inc. has no controlling shareholder.
The full transparency notification is available
on the Galapagos website.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG)
discovers and develops small molecule medicines with novel modes of
action, three of which show promising patient results and are
currently in late-stage development in multiple diseases. The
Company's pipeline comprises Phase 3 through to discovery programs
in inflammation, fibrosis, osteoarthritis and other indications.
Galapagos' ambition is to become a leading global biopharmaceutical
company focused on the discovery, development and commercialization
of innovative medicines. More information at www.glpg.com.
Galapagos
Contacts |
|
Investors: |
Media: |
Elizabeth
Goodwin |
Carmen
Vroonen |
VP IR |
Senior Director
Communications |
+1 781 460
1784 |
+32 473 824
874 |
|
|
Sofie Van Gijsel
|
Evelyn Fox |
Director
IR |
Director
Communications |
+32 485 19 14
15 |
+31 6 53 591
999 |
ir@glpg.com |
communications@glpg.com |
1 Belgian Act of 2 May 2007 on the disclosure of major
shareholdings in issuers whose shares are admitted to trading on a
regulated market and regarding miscellaneous provisions.
- Transparency Notification PR EN
Galapagos (EU:GLPG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Sep 2023 to Sep 2024